NovaBridge Biosciences beat EPS estimates 75% of the time across 4 reported quarters (3 beats, 1 misses), averaging +16.6% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.14 | $-0.07 | +50.0% | Beat | |
| Q1 FY26 | not reported | $-0.04 | not reported | not reported | |
| Q2 FY25 | $-0.10 | $-0.07 | +30.0% | Beat | |
| Q1 FY25 | $-0.07 | $-0.04 | +42.9% | Beat | |
| Q3 FY24 | $-0.16 | $-0.25 | -56.3% | Miss | |
| Q2 FY24 | not reported | $-0.07 | not reported | not reported | |
| Q4 FY19 | not reported | $-17.05 | not reported | not reported |
Back to NBP overview · NBP holders · NBP KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.